Evidence map›Paper›PMID 40854181›Full record

ArticleJournal of medical Internet research2025

Digital Tools for People Without an Alzheimer Disease or Dementia Diagnosis: Scoping Review.

Tanja J de Rijke, Thomas Engelsma, Chi Him Ng, Kyra Km Kaijser, Henk Herman Nap, Ellen Ma Smets, Leonie Nc Visser

Abstract readScoping Review
In one paragraph

Article in Journal of medical Internet research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tanja J de RijkeDepartment of Medical Psychology, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands, 31 205663622.ORCID http://orcid.org/0009-0009-8077-2214
Thomas EngelsmaDigital Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-8889-1669
Chi Him NgeHealth Living & Learning Lab Amsterdam, Department of Medical Informatics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0009-0003-7298-9049
Kyra Km KaijserDepartment of Medical Psychology, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands, 31 205663622.ORCID http://orcid.org/0009-0005-1605-7364
Henk Herman NapVilans Centre of Expertise for Long-Term Care, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-2545-0510
Ellen Ma SmetsDepartment of Medical Psychology, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands, 31 205663622.ORCID http://orcid.org/0000-0002-8145-8595
Leonie Nc VisserDepartment of Medical Psychology, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, Amsterdam, 1105 AZ, The Netherlands, 31 205663622.ORCID http://orcid.org/0000-0003-3487-7938

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The field of Alzheimer disease (AD) has been moving toward earlier detection, personalized assessment of dementia risk, and dementia prevention. In the near future, a gap is expected between the growing demand for Alzheimer-related health care and a shrinking workforce. Responsibility is increasingly assigned to individuals to take an active role in their own brain health management and dementia prevention. Digital tools are thought to offer support regarding these processes. Objective: The aim of this scoping review is to create an overview of digital tools published in scientific literature in the context of AD and dementia aimed at people without an AD or dementia diagnosis as primary end users interacting with these digital tools. Additionally, we aim to gain insight into study sample diversity, the stage of maturity and evaluation of these tools, and recommended future directions. Methods: PubMed, IEEE Xplore, Ovid, and Web of Science were searched in January 2023, using terms related to AD and dementia, (pre-)disease stages, digital tools, and various purposes of digital tools. Two independent reviewers screened the titles and abstracts of 2811 records and subsequently 408 full-text articles, based on inclusion and exclusion criteria. Articles on tools targeting those with an AD or dementia diagnosis were excluded. Data extraction included information on the sample characteristics, the digital tool, stage of maturity and evaluation, and future (research) directions. Results: We included 39 articles, which were aimed at primary prevention (14/39, 36%), secondary prevention (11/39, 28%), daily life support (8/39, 21%), self-administered screening (4/39, 10%), or decision-making (2/39, 5%). Variation in the study sample emerged regarding cognitive abilities (healthy: 11/39, 28%; mild cognitive impairment: 12/39, 31%; [subjective] cognitive impairment: 9/39, 23%; "no dementia": 1/39, 3%; and variation of cognitive abilities: 6/39, 15%). Less variation was found regarding sex (>50% female: 27/39, 69%), education (>50% high education: 13/39, 33%), and age (>50% >60 y: 23/39, 59%). Few articles reported on ethnicity (12/39, 31%) and digital literacy (11/39, 28%). Most tools were in an early evaluation and maturity stage (31/39, 80%), comprising preprototyping (1/35, 3%), prototyping (15/35, 43%), pilot testing (19/35, 54%), efficacy testing (18/40, 45%), usability testing (12/40, 30%), and feasibility testing (10/40, 25%). Future (research) directions comprised the need for further tool development, attention to diversity, and study advancements, such as large-scale longitudinal studies. Conclusions: Almost 80% of tools as reported on in academic literature are in early development comprising early stages of maturity and evaluation. Studies and evidence gathered for digital tools developed in the context of AD or dementia aimed at people without an AD or dementia diagnosis are thus preliminary and further development, research, and policy are required before these tools can be implemented for assessing, supporting, and preventing cognitive decline.

Indexed as

Alzheimer DiseaseDementiaHumansbrain healthdigital toolsdiversityeHealthelectronic healthequityfuture directionsimpact evaluationimplementationmHealthmobile healthstage of maturity

Identifiers

PMID40854181
PMCPMC12377699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.